Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Topics
3. Definition of DILI
4. Types of DILI
5. Mechanisms of DILI (1)
6. Mechanisms of DILI (2)
7. The case of acetominophen intoxication
8. Drugs that potentially cause liver injury
9. Safety withdrawals 1960-1999
10. Signals of DILI in drug development
11. Scope of DILI
12. Cost of drug development
13. Epidemiology of DILI (1)
14. Etiology of ALF in the USA
15. Tip of the iceberg
16. Epidemiology of DILI (2)
17. Clinical patterns of DILI
18. Image of a normal liver (1)
19. Image of a normal liver (2)
20. Hepatocellular liver injury (1)
21. Hepatocellular liver injury (2)
22. Biochemistry of hepatocellular injury
23. Cholestatic liver injury
24. Biochemistry of cholestatic injury
25. What comprises liver injury?
26. What comprises liver injury in 2008?
27. Adaptation to injury (tolerance)
28. Adaptation in DILI
29. Toxicity grading in clinical trials
30. Jaundice and DILI
31. Hepatocellular jaundice
32. Bile lakes and apoptotic hepatocytes
33. Acute hepatocellular jaundice
34. Cholestatic jaundice
35. Common "signatures" of DILI
36. Susceptibility factors for DILI
37. Key elements in diagnosis
38. Diagnosis of DILI
39. Causality assessment tools in DILI
40. Causality assessment
41. Management of DILI
42. Rumack-Matthew nomogram
43. Monitoring in clinical practice
44. DILIN
45. Summary
46. Thank you

Topics Covered

• Definition of drug induced liver injury (DILI)
• Types and mechanisms of DILI
• Safety withdrawals
• Signals of DILI in drug development
• Epidemiology of DILI
• Clinical patterns
• Hepatocellular liver injury
• Cholestatic liver injury
• What comprises liver injury?
• Adaptation to injury
• Toxicity grading in clinical trials
• Jaundice
• Common signatures of DILI
• Susceptibility factors for DILI
• Key elements in diagnosis
• Causality assessment tools
• Management of DILI
• Monitoring in clinical practice

Links

Series:

• Non-Clinical Testing for Toxicity of Pharmaceuticals

Categories:

• Clinical Practice
• Metabolism & Nutrition
• Pharmaceutical Sciences

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Publication History

• Published on July 30, 2009

Financial Disclosures

• Prof. Victor Navarro has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.